Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants

Next Previous
Trial Profile

An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALX-001 (Primary) ; Caffeine; Dextromethorphan; Midazolam
  • Indications Alzheimer's disease; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Allyx Therapeutics

Most Recent Events

  • 07 Feb 2025 Planned End Date changed from 1 Mar 2025 to 15 Oct 2025.
  • 07 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 3 Apr 2025.
  • 20 Nov 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top